EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Korro Bio's Enterprise Value is $141.75 Mil.
Korro Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-77.98 Mil. Therefore, Korro Bio's EV-to-FCF for today is -1.82.
The historical rank and industry rank for Korro Bio's EV-to-FCF or its related term are showing as below:
KRRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.1 Med: -2.81 Max: -1.59
Current: -1.59
During the past 4 years, the highest EV-to-FCF of Korro Bio was -1.59. The lowest was -4.10. And the median was -2.81.
KRRO's EV-to-FCF is ranked worse than 100% of 424
companies
in the Biotechnology industry
Industry Median: 3.285
vs KRRO: -1.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Korro Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Korro Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korro Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Korro Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Korro Bio's EV-to-FCF falls into.
Korro Bio's current Enterprise Value is $141.75 Mil.
Korro Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-77.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio (NAS:KRRO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Korro Bio's share price for today is $23.76.
Korro Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Korro Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Korro Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your 